Innovotherapeutics has signed a joint research and technology transfer option contract with Riga Chem Bioscience to develop next-generation ADC treatments aimed at overcoming the limitations and resistance of current ADCs

The collaboration will combine Innovotherapeutics’ new mechanism payloads (low-molecular compounds) with Riga ChemBio’s ConjuAll ADC technology, a next-generation linker platform

Riga ChemBio will secure exclusive rights to research, development, and commercialization for five targets as part of the agreement, with private financial terms, including milestones and royalties

Innovotherapeutics is utilizing its AI platform, DeepZema, for efficient drug discovery and is expanding its business to include the development of new payloads for cancer treatments